These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 39025091)

  • 21. Longitudinal serological assessment of type VI collagen turnover is related to progression in a real-world cohort of idiopathic pulmonary fibrosis.
    Jessen H; Hoyer N; Prior TS; Frederiksen P; Rønnow SR; Karsdal MA; Leeming DJ; Bendstrup E; Sand JMB; Shaker SB
    BMC Pulm Med; 2021 Nov; 21(1):382. PubMed ID: 34814865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Matrix metalloproteinase-10: a novel biomarker for idiopathic pulmonary fibrosis.
    Sokai A; Handa T; Tanizawa K; Oga T; Uno K; Tsuruyama T; Kubo T; Ikezoe K; Nakatsuka Y; Tanimura K; Muro S; Hirai T; Nagai S; Chin K; Mishima M
    Respir Res; 2015 Sep; 16():120. PubMed ID: 26415518
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry.
    Todd JL; Neely ML; Overton R; Durham K; Gulati M; Huang H; Roman J; Newby LK; Flaherty KR; Vinisko R; Liu Y; Roy J; Schmid R; Strobel B; Hesslinger C; Leonard TB; Noth I; Belperio JA; Palmer SM;
    Respir Res; 2019 Oct; 20(1):227. PubMed ID: 31640794
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Change in forced vital capacity and associated subsequent outcomes in patients with newly diagnosed idiopathic pulmonary fibrosis.
    Reichmann WM; Yu YF; Macaulay D; Wu EQ; Nathan SD
    BMC Pulm Med; 2015 Dec; 15():167. PubMed ID: 26714746
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
    Noble PW; Albera C; Bradford WZ; Costabel U; Glassberg MK; Kardatzke D; King TE; Lancaster L; Sahn SA; Szwarcberg J; Valeyre D; du Bois RM;
    Lancet; 2011 May; 377(9779):1760-9. PubMed ID: 21571362
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of surgical lung biopsy on lung function and survival in patients with idiopathic pulmonary fibrosis in a multi-centre registry cohort.
    Marcoux V; Lok SD; Mondal P; Assayag D; Fisher JH; Shapera S; Morisset J; Manganas H; Fell CD; Hambly N; Cox PG; Kolb M; Gershon AS; To T; Sadatsafavi M; Khalil N; Wong AW; Wilcox PG; Ryerson CJ; Vu T; Johannson KA
    Respirology; 2024 Jul; 29(7):596-604. PubMed ID: 38436522
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Increased monocyte count and red cell distribution width as prognostic biomarkers in patients with Idiopathic Pulmonary Fibrosis.
    Karampitsakos T; Torrisi S; Antoniou K; Manali E; Korbila I; Papaioannou O; Sampsonas F; Katsaras M; Vasarmidi E; Papakosta D; Domvri K; Fouka E; Organtzis I; Daniil Z; Dimeas I; Kirgou P; Gourgoulianis KI; Papanikolaou IC; Markopoulou K; Kounti G; Tsapakidou E; Papadopoulou E; Tatsis K; Gogali A; Kostikas K; Tzilas V; Chrysikos S; Papiris S; Bouros D; Kreuter M; Tzouvelekis A
    Respir Res; 2021 May; 22(1):140. PubMed ID: 33952261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blood biomarkers MMP-7 and SP-A: predictors of outcome in idiopathic pulmonary fibrosis.
    Song JW; Do KH; Jang SJ; Colby TV; Han S; Kim DS
    Chest; 2013 May; 143(5):1422-1429. PubMed ID: 23715088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic and predictive biomarkers for patients with idiopathic pulmonary fibrosis treated with pirfenidone: post-hoc assessment of the CAPACITY and ASCEND trials.
    Neighbors M; Cabanski CR; Ramalingam TR; Sheng XR; Tew GW; Gu C; Jia G; Peng K; Ray JM; Ley B; Wolters PJ; Collard HR; Arron JR
    Lancet Respir Med; 2018 Aug; 6(8):615-626. PubMed ID: 30072107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pursuing Clinical Predictors and Biomarkers for Progression in ILD: Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry.
    Chang SE; Jia G; Gao X; Schiffman C; Gupta S; Wolters P; Neighbors M
    Lung; 2024 Jun; 202(3):269-273. PubMed ID: 38753183
    [TBL] [Abstract][Full Text] [Related]  

  • 31. LPA
    Decato BE; Leeming DJ; Sand JMB; Fischer A; Du S; Palmer SM; Karsdal M; Luo Y; Minnich A
    Respir Res; 2022 Mar; 23(1):61. PubMed ID: 35303880
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled study.
    Maher TM; Stowasser S; Nishioka Y; White ES; Cottin V; Noth I; Selman M; Rohr KB; Michael A; Ittrich C; Diefenbach C; Jenkins RG;
    Lancet Respir Med; 2019 Sep; 7(9):771-779. PubMed ID: 31326319
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis.
    Zappala CJ; Latsi PI; Nicholson AG; Colby TV; Cramer D; Renzoni EA; Hansell DM; du Bois RM; Wells AU
    Eur Respir J; 2010 Apr; 35(4):830-6. PubMed ID: 19840957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Eligibility for anti-fibrotic treatment in idiopathic pulmonary fibrosis depends on the predictive equation used for pulmonary function testing.
    Burgess A; Goon K; Brannan JD; Attia J; Palazzi K; Oldmeadow C; Corte TJ; Glaspole I; Goh N; Keir G; Allan H; Chapman S; Cooper W; Ellis S; Hopkins P; Moodley Y; Reynolds P; Zappala C; Macansh S; Grainge C
    Respirology; 2019 Oct; 24(10):988-995. PubMed ID: 30924257
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Disease progression in idiopathic pulmonary fibrosis with mild physiological impairment: analysis from the Australian IPF registry.
    Jo HE; Glaspole I; Moodley Y; Chapman S; Ellis S; Goh N; Hopkins P; Keir G; Mahar A; Cooper W; Reynolds P; Haydn Walters E; Zappala C; Grainge C; Allan H; Macansh S; Corte TJ
    BMC Pulm Med; 2018 Jan; 18(1):19. PubMed ID: 29370786
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pulmonary artery enlargement and cystic fibrosis pulmonary exacerbations: a cohort study.
    Wells JM; Farris RF; Gosdin TA; Dransfield MT; Wood ME; Bell SC; Rowe SM
    Lancet Respir Med; 2016 Aug; 4(8):636-645. PubMed ID: 27298019
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers of collagen synthesis predict progression in the PROFILE idiopathic pulmonary fibrosis cohort.
    Organ LA; Duggan AR; Oballa E; Taggart SC; Simpson JK; Kang'ombe AR; Braybrooke R; Molyneaux PL; North B; Karkera Y; Leeming DJ; Karsdal MA; Nanthakumar CB; Fahy WA; Marshall RP; Jenkins RG; Maher TM
    Respir Res; 2019 Jul; 20(1):148. PubMed ID: 31299951
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Idiopathic Pulmonary Fibrosis: Prospective, Case-Controlled Study of Natural History and Circulating Biomarkers.
    Raghu G; Richeldi L; Jagerschmidt A; Martin V; Subramaniam A; Ozoux ML; Esperet CA; Soubrane C
    Chest; 2018 Dec; 154(6):1359-1370. PubMed ID: 30526970
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial.
    Behr J; Prasse A; Kreuter M; Johow J; Rabe KF; Bonella F; Bonnet R; Grohe C; Held M; Wilkens H; Hammerl P; Koschel D; Blaas S; Wirtz H; Ficker JH; Neumeister W; Schönfeld N; Claussen M; Kneidinger N; Frankenberger M; Hummler S; Kahn N; Tello S; Freise J; Welte T; Neuser P; Günther A;
    Lancet Respir Med; 2021 May; 9(5):476-486. PubMed ID: 33798455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating Plasma Biomarkers of Survival in Antifibrotic-Treated Patients With Idiopathic Pulmonary Fibrosis.
    Adegunsoye A; Alqalyoobi S; Linderholm A; Bowman WS; Lee CT; Pugashetti JV; Sarma N; Ma SF; Haczku A; Sperling A; Strek ME; Noth I; Oldham JM
    Chest; 2020 Oct; 158(4):1526-1534. PubMed ID: 32450241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.